Will 2009 Bring Innovation? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Will 2009 Bring Innovation?
Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.


Pharmaceutical Technology
Volume 33, Issue 1, pp. 14


Erik Greb
Reducing healthcare costs, a priority for President Obama, will be important for everyone during our economic crisis. Promoting cheap generic drugs as alternatives to branded medicines is one possible approach to the problem.

A paper published in the Dec. 3, 2008 issue of The Journal of the American Medical Association supports this strategy. Researchers analyzed studies conducted between 1984 and 2008 that compared the clinical results of treatment with branded and generic cardiovascular drugs. Clinical equivalence was established in 29 of 32 randomized controlled trials, and the authors concluded that evidence did not support the idea that branded therapies were superior to generic drugs in the treatment of cardiovascular disease.

If this report encourages patients, doctors, and health plans to use generic drugs, how will Big Pharma deal with the competition? It seems likely that manufacturers will intensify their efforts to develop new drug-delivery methods for existing products. In a September 2008 press release, Frost and Sullivan said that patent expiries were spurring investment in novel delivery systems. Interest in pulmonary, transdermal, and nanotechnological routes is growing rapidly, the company said.

Generic competition and the economic crunch might be blessings in disguise for Big Pharma. If these pressures lead companies to develop safe, innovative, and convenient delivery methods for existing drugs, then patients and industry will share the benefits.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ğRead Erik's blogs at http://blog.PharmTech.com/.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here